Cargando…

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ 2 years o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortes, Jorge E., de Lima, Marcos, Dombret, Hervé, Estey, Elihu H., Giralt, Sergio A., Montesinos, Pau, Röllig, Christoph, Venditti, Adriano, Wang, Eunice S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559451/ https://www.ncbi.nlm.nih.gov/pubmed/33059764 http://dx.doi.org/10.1186/s13045-020-00975-2

Ejemplares similares

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020)

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

Gemtuzumab Ozogamicin: Back Again
por: Selby, Chris, et al.
Publicado: (2019)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
por: Pautas, Cécile, et al.
Publicado: (2021)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
por: Gottardi, Michele, et al.
Publicado: (2017)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
por: Yu, Bo, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
por: Mareque, Maria, et al.
Publicado: (2021)

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
por: Godwin, Colin D., et al.
Publicado: (2022)

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
por: Mamolo, Carla, et al.
Publicado: (2020)

Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia
por: Hååg, Petra, et al.
Publicado: (2022)

Gemtuzumab ozogamicin: Various toxicities: 2 case reports
Publicado: (2017)

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK
por: Russell-Smith, T. Alexander, et al.
Publicado: (2021)

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
por: Lambert, Juliette, et al.
Publicado: (2019)

Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)
por: Vegunta, Rathnamitreyee, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
por: Fostvedt, Luke K., et al.
Publicado: (2019)

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
por: Awada, Hassan, et al.
Publicado: (2023)

Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a ‘Real-Life’ Study
por: Laurino, Marica, et al.
Publicado: (2020)

The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience
por: Açar, İbrahim Halil, et al.
Publicado: (2023)

PB1853: OUTCOMES REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY MANIFESTATIONS AFTER GEMTUZUMAB OZOGAMICIN THERAPY
por: Ayubova, Bella, et al.
Publicado: (2023)

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
por: Renneville, Aline, et al.
Publicado: (2014)

A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia
por: Montesinos, Pau, et al.
Publicado: (2023)

Effect and safety of gemtuzumab ozogamicin for the treatment of patients with acute myeloid leukaemia: a systematic review protocol
por: Muhamad, Nor A, et al.
Publicado: (2020)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group
por: Niktoreh, Naghmeh, et al.
Publicado: (2019)

Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia
por: Khan, Naeem, et al.
Publicado: (2016)

Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia
por: Zhang, Nan, et al.
Publicado: (2020)

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
por: Küçükdiler, Ayşe Hilal Eroğlu, et al.
Publicado: (2021)

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
por: Castaño-Bonilla, Tamara, et al.
Publicado: (2022)

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
por: Zaytsev, Daniil, et al.
Publicado: (2020)

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
por: Fultang, Livingstone, et al.
Publicado: (2019)

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
por: Lamba, Jatinder K., et al.
Publicado: (2021)

Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin
por: Wijnen, Noa E, et al.
Publicado: (2023)

Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg(®)) in children with relapsed/refractory myeloid leukemia
por: Brethon, Benoit, et al.
Publicado: (2006)

Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin
por: Kurimoto, M, et al.
Publicado: (2013)

Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia
por: AZUMA, YOSHIKO, et al.
Publicado: (2016)

Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
por: Jawad, Mays, et al.
Publicado: (2012)

Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy
por: Cairoli, Roberto, et al.
Publicado: (2023)

Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia
por: Zhang, Cathy C, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kghlbc3k5cnph0eqjvmobod70u